Immuron Limited (ASX:IMC) has entered into an agreement with Immune Biologics Pty Ltd to develop and commercialise its IMM-124E treatment for short-term alcohol-induced liver toxicity.
Under the agreement, Immune Biologics will carry out clinical trials designed to test the efficacy of IMM-124E.
The principle underlying these studies is that the anti-LPS activity of IMM-124E is the same underlying mechanism that governs the treatment of both non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH), thus enabling the testing and use of IMM-124E in this third short-term clinical indication.
Should the trials be successful, Immuron will sell IMM-124E to Immune Biologics under a worldwide license specifically for toxicity associated with short-term alcohol intake.
Immune Biologics is associated with Peter Anastasiou, Immuron’s largest shareholder through various related entities.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.